Top

Published in:

Open Access 01-10-2021 | Breast Cancer | Original Article

Cytoplasmic DDX3 as prognosticator in male breast cancer

Authors: Carmen C. van der Pol, Cathy B. Moelans, Quirine F. Manson, Marilot C. T. Batenburg, Elsken van der Wall, Inne Borel Rinkes, Lenny Verkooijen, Venu Raman, Paul J. van Diest

Published in: Virchows Archiv | Issue 4/2021

Abstract

Male breast cancer (MBC) is a rare disease. Due to its rarity, treatment is still directed by data mainly extrapolated from female breast cancer (FBC) treatment, despite the fact that it has recently become clear that MBC has its own molecular characteristics. DDX3 is a RNA helicase with tumor suppressor and oncogenic potential that was described as a prognosticator in FBC and can be targeted by small molecule inhibitors of DDX3. The aim of this study was to evaluate if DDX3 is a useful prognosticator for MBC patients. Nuclear as well as cytoplasmic DDX3 expression was studied by immunohistochemistry in a Dutch retrospective cohort of 106 MBC patients. Differences in 10-year survival by DDX3 expression were analyzed using log-rank test. The association between clinicopathologic variables, DDX3 expression, and survival was tested in uni- and multivariate Cox-regression analysis. High cytoplasmic DDX3 was associated with high androgen receptor (AR) expression while low nuclear DDX3 was associated with negative lymph node status. Nuclear and cytoplasmic DDX3 were not associated with each other. In a univariate analysis, high cytoplasmic DDX3 (p = 0.045) was significantly associated with better 10-year overall survival. In multivariate analyses, cytoplasmic DDX3 had independent prognostic value (p = 0.017). In conclusion, cytoplasmic DDX3 expression seems to be a useful prognosticator in MBC, as high cytoplasmic DDX3 indicated better 10-year survival.

Cardoso F, Bartlett JMS, Slaets L et al (2018) Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program. Ann Oncol 29(2):405–417. https://doi.org/10.1093/annonc/mdx651CrossRefPubMed

Kornegoor R, Verschuur-Maes AHJ, Buerger H et al (2012) Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 25(3):398–404. https://doi.org/10.1038/modpathol.2011.174CrossRefPubMed

Kornegoor R, Verschuur-Maes AHJ, Buerger H et al (2012) Immunophenotyping of male breast cancer. Histopathology 61(6):1145–1155. https://doi.org/10.1111/j.1365-2559.2012.04330.xCrossRefPubMed

Abreu MH, Afonso N, Abreu PH et al (2016) Male breast cancer: looking for better prognostic subgroups. Breast 26:18–24. https://doi.org/10.1016/j.breast.2015.12.001CrossRefPubMed

Fentiman IS (2018) The biology of male breast cancer. Breast 38:132–135. https://doi.org/10.1016/j.breast.2018.01.001CrossRefPubMed

Wang F, Shu X, Meszoely I et al (2019) Overall mortality after diagnosis of breast cancer in men vs women. JAMA Oncol 5(11):1589–1596. https://doi.org/10.1001/jamaoncol.2019.2803CrossRefPubMedPubMedCentral

Miao H, Verkooijen HM, Chia K-S et al (2011) Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol 29(33):4381–4386. https://doi.org/10.1200/JCO.2011.36.8902CrossRefPubMed

Contractor KB, Kaur K, Rodrigues GS et al (2008) Male breast cancer: is the scenario changing. World J SurgOncol 6:58. https://doi.org/10.1186/1477-7819-6-58CrossRef

Guenther U, Weinberg DE, Zubradt MM et al (2018) The helicase Ded1p controls use of near-cognate translation initiation codons in 5′ UTRs. Nature 559(7712):130–134. https://doi.org/10.1038/s41586-018-0258-0CrossRefPubMedPubMedCentral

10.

Brennan R, Haap-Hoff A, Gu L et al (2018) Investigating nucleo-cytoplasmic shuttling of the human DEAD-box helicase DDX3. Eur J Cell Biol 97(7):501–511. https://doi.org/10.1016/j.ejcb.2018.08.001CrossRefPubMed

11.

Chen H-H, Yu H-I, Cho W-C et al (2015) DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway. Oncogene 34(21):2790–2800. https://doi.org/10.1038/onc.2014.190CrossRefPubMed

12.

Bol GM, Xie M, Raman V (2015) DDX3, a potential target for cancer treatment. Mol Cancer 14(1). https://doi.org/10.1186/s12943-015-0461-7

13.

Sun M, Zhou T, Jonasch E et al (2013) DDX3 regulates DNA damage-induced apoptosis and p53 stabilization. BiochimBiophysActa - Mol Cell Res 1833(6):1489–1497. https://doi.org/10.1016/j.bbamcr.2013.02.026CrossRef

14.

Vellky JE, Ricke EA, Huang W, Ricke WA (2019) Expression and localization of DDX3 in prostate cancer progression and metastasis. Am J Pathol 189(6):1256–1267. https://doi.org/10.1016/j.ajpath.2019.02.011CrossRefPubMedPubMedCentral

15.

Botlagunta M, Vesuna F, Mironchik Y et al (2008) Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene 27(28):3912–3922. https://doi.org/10.1038/onc.2008.33CrossRefPubMedPubMedCentral

16.

Heerma van Voss MR, Schrijver WAME, ter Hoeve ND et al (2017) The prognostic effect of DDX3 upregulation in distant breast cancer metastases. Clin Exp Metastasis 34(1):85–92. https://doi.org/10.1007/s10585-016-9832-8CrossRefPubMed

17.

He Y, Zhang D, Yang Y et al (2018) A double-edged function of DDX3, as an oncogene or tumor suppressor, in cancer progression (Review). Oncol Rep 39(3):883–892. https://doi.org/10.3892/or.2018.6203CrossRefPubMed

18.

Lin TC (2020) DDX3X multifunctionally modulates tumor progression and serves as a prognostic indicator to predict cancer outcomes. Int J Mol Sci 21(1). https://doi.org/10.3390/ijms21010281

19.

Botlagunta M, Krishnamachary B, Vesuna F et al (2011) Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells. Batra SK, ed. PLoS One 6(3):e17563. https://doi.org/10.1371/journal.pone.0017563

20.

Zhao L, Mao Y, Zhou J et al (2016) Multifunctional DDX3: Dual roles in various cancer development and its related signaling pathways. Am J Cancer Res 6(2):387–402PubMedPubMedCentral

21.

Chang PC, Chi CW, Chau GY et al (2006) DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. Oncogene 25(14):1991–2003. https://doi.org/10.1038/sj.onc.1209239CrossRefPubMed

22.

Heerma van Voss MR, van Kempen PMW, Noorlag R et al (2015) DDX3 has divergent roles in head and neck squamous cell carcinomas in smoking versus non-smoking patients. Oral Dis 21(2):270–271. https://doi.org/10.1111/odi.12299CrossRefPubMed

23.

Bol GM, Vesuna F, Xie M et al (2015) Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med 7(5):648–669. https://doi.org/10.15252/emmm.201404368CrossRefPubMedPubMedCentral

24.

Tantravedi S, Vesuna F, Winnard PT et al (2019) Targeting DDX3 in medulloblastoma using the small molecule inhibitor RK-33. Transl Oncol 12(1):96–105. https://doi.org/10.1016/j.tranon.2018.09.002CrossRef

25.

Heerma van Voss MR, Vesuna F, Bol GM et al (2018) Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment. Oncogene 37(1):63–74. https://doi.org/10.1038/onc.2017.308CrossRefPubMed

26.

Bol GM, Raman V, van der Groep P et al (2013) Expression of the RNA Helicase DDX3 and the hypoxia response in breast cancer. PLoS ONE 8(5):1–7. https://doi.org/10.1371/journal.pone.0063548CrossRef

27.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410. https://doi.org/10.1111/j.1365-2559.1991.tb00229.xCrossRefPubMed

28.

Hammond MEH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. https://doi.org/10.1200/JCO.2009.25.6529CrossRefPubMedPubMedCentral

29.

Verschuur-Maes AHJ, Kornegoor R, de Bruin PC et al (2014) Do columnar cell lesions exist in the male breast? Histopathology 64(6):818–825. https://doi.org/10.1111/his.12333CrossRefPubMed

30.

Lacle MM, van der Pol C, Witkamp A et al (2013) Prognostic value of mitotic index and Bcl2 expression in male breast cancer. PLoS ONE 8(4):e60138. https://doi.org/10.1371/journal.pone.0060138CrossRefPubMedPubMedCentral

31.

Angus AG, Dalrymple D, Boulant S et al (2010) Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol 91(1):122–132. https://doi.org/10.1099/vir.0.015909-0CrossRefPubMedPubMedCentral

32.

Yedavalli VSRK, Neuveut C, Chi YH et al (2004) Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 119(3):381–392. https://doi.org/10.1016/j.cell.2004.09.029CrossRefPubMed

33.

Budczies J, Klauschen F, Sinn BV et al (2012) Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7(12):1–7. https://doi.org/10.1371/journal.pone.0051862CrossRef

34.

Heerma-van-Voss MR, Vesuna F, Trumpi K et al (2015) Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer. Oncotarget 6(29):28312–28326. https://doi.org/10.18632/oncotarget.4873CrossRefPubMed

35.

Heerma-Van-Voss MR, Vesuna F, Bol GM et al (2017) Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer. Onco Targets Ther 10:3501–3513. https://doi.org/10.2147/OTT.S140639CrossRefPubMedPubMedCentral

36.

Xie M, Vesuna F, Tantravedi S et al (2016) RK-33 Radiosensitizes Prostate cancer cells by blocking the RNA helicase DDX3. Cancer Res 76(21):6340–6350. https://doi.org/10.1158/0008-5472.CAN-16-0440CrossRefPubMedPubMedCentral

37.

Chen WJ, Wang WT, Tsai TY et al (2017) DDX3 localizes to the centrosome and prevents multipolar mitosis by epigenetically and translationally modulating p53 expression. Sci Rep 7(1):1–20. https://doi.org/10.1038/s41598-017-09779-wCrossRef

38.

Botlagunta M, Krishnamachary B, Vesuna F et al (2011) Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells. PLoS ONE 6(3):1–10. https://doi.org/10.1371/journal.pone.0017563CrossRef

39.

Vermeulen MA, Slaets L, Cardoso F et al (2017) Pathological characterisation of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program. Eur J Cancer 82(March):219–227. https://doi.org/10.1016/j.ejca.2017.01.034CrossRefPubMed

40.

Matsumura T, Endo T, Isotani A et al (2019) An azoospermic factor gene, Ddx3y and its paralog, Ddx3x are dispensable in germ cells for male fertility. J Reprod Dev 65(2):121–128. https://doi.org/10.1262/jrd.2018-145CrossRefPubMedPubMedCentral

41.

Chan CH, Chen CM, Lee YHW et al (2019) DNA damage, liver injury, and tumorigenesis: consequences of DDX3X loss. Mol Cancer Res 17(2):555–566. https://doi.org/10.1158/1541-7786.MCR-18-0551CrossRefPubMed

42.

Lee CH, Lin SH, Yang SF et al (2014) Low/negative expression of DDX3 might predict poor prognosis in non-smoker patients with oral cancer. Oral Dis 20(1):76–83. https://doi.org/10.1111/odi.12076CrossRefPubMed

43.

Hwang K, Kim YA, Kim J et al (2020) Influence of androgen receptor on the prognosis of breast cancer. J Clin Med 9(4):1083. https://doi.org/10.3390/jcm9041083CrossRefPubMedCentral

44.

Vellky JE, McSweeney ST, Ricke EA et al (2020) RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: a mechanism of castration resistance. Proc Natl AcadSci U S A 117(45):28092–28101. https://doi.org/10.1073/pnas.2008479117CrossRef

45.

Lash TL, Fox MP, Westrup JL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220. https://doi.org/10.1007/s10549-006-9193-0CrossRefPubMed

Title: Cytoplasmic DDX3 as prognosticator in male breast cancer
Authors: Carmen C. van der Pol
Cathy B. Moelans
Quirine F. Manson
Marilot C. T. Batenburg
Elsken van der Wall
Inne Borel Rinkes
Lenny Verkooijen
Venu Raman
Paul J. van Diest
Publication date: 01-10-2021
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Androgens
Published in: Virchows Archiv / Issue 4/2021
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-021-03107-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cytoplasmic DDX3 as prognosticator in male breast cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma

Correlating SS18-SSX immunohistochemistry (IHC) with SS18 fluorescent in situ hybridization (FISH) in synovial sarcomas: a study of 36 cases

Transbronchial biopsies’ histopathological findings leading to successful late steroid therapy in Covid-19 acute respiratory failure

Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis

High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia

Concurrent epithelioid hemangioma and diffuse cavernous hemangioma in the rectum clinically mimicking a malignant tumor: a case report